Compositions and methods of treating amyotrophic lateral sclerosis (als)
AssigneeVoyager Therapeutics, Inc.
InventorsDinah Wen-Yee SAH, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
Life of this patent
Estimating the term…
Abstract
The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
Claims21
1-25. (canceled)
An adeno-associated viral (AAV) vector genome comprising a nucleic acid positioned between two inverted terminal repeats (ITRs), wherein the nucleic acid encodes a sense strand sequence and an antisense strand sequence of a siRNA, wherein the sense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences listed in Table 3, Table 11 or Table 14 and the antisense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences listed in Table 3, Table 11 or Table 14, and wherein the sense strand sequence and the antisense strand sequence share a region of complementarity of at least 17 nucleotides in length.
A siRNA for inhibiting expression of SOD1 comprising a sense strand sequence and an antisense strand sequence, wherein the sense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequence of sequences listed in Table 3, Table 11 or Table 14 and the antisense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequence of sequences listed in Table 3, Table 11 or Table 14, and wherein said sense strand sequence and antisense strand sequence share a region of complementarity of at least 17 nucleotides in length.
A method for treating and/or ameliorating amyotrophic lateral sclerosis (ALS) in a subject, the method comprising administering to the subject an AAV particle comprising an AAV vector genome comprising a nucleic acid positioned between two inverted terminal repeats (ITRs), and wherein the nucleic acid sequence encodes a sense strand sequence and an antisense strand sequence of a siRNA, wherein the sense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences listed in Table 3, Table 11 or Table 14 and the antisense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences listed in Table 3, Table 11 or Table 14;
- wherein the sense strand sequence and the antisense strand sequence share a region of complementarity of at least 17 nucleotides in length;
- thereby treating the subject.
Dependencies are inferred from the claim text.